[{"address1": "12265 El Camino Real", "address2": "Suite 350", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "858 727 1040", "fax": "858 614 7007", "website": "https://www.connectbiopharm.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.", "fullTimeEmployees": 81, "maxAge": 86400, "priceHint": 4, "previousClose": 1.43, "open": 1.39, "dayLow": 1.35, "dayHigh": 1.56, "regularMarketPreviousClose": 1.43, "regularMarketOpen": 1.39, "regularMarketDayLow": 1.35, "regularMarketDayHigh": 1.56, "beta": -0.351, "forwardPE": 0.85276073, "volume": 58660, "regularMarketVolume": 58660, "averageVolume": 117841, "averageVolume10days": 72350, "averageDailyVolume10Day": 72350, "ask": 1.45, "askSize": 400, "marketCap": 76593168, "fiftyTwoWeekLow": 0.535, "fiftyTwoWeekHigh": 2.84, "fiftyDayAverage": 1.61676, "twoHundredDayAverage": 1.29569, "currency": "USD", "enterpriseValue": -41647980, "floatShares": 16049401, "sharesOutstanding": 55103000, "sharesShort": 54141, "sharesShortPriorMonth": 83144, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.001, "heldPercentInsiders": 0.41272, "heldPercentInstitutions": 0.43808997, "shortRatio": 0.69, "shortPercentOfFloat": 0.0017, "impliedSharesOutstanding": 56732600, "bookValue": 1.834, "priceToBook": 0.7579062, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -59503000, "trailingEps": -1.08, "forwardEps": 1.63, "enterpriseToEbitda": 0.648, "52WeekChange": 0.18803418, "SandP52WeekChange": 0.26238096, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "CNTB", "underlyingSymbol": "CNTB", "shortName": "Connect Biopharma Holdings Limi", "longName": "Connect Biopharma Holdings Limited", "firstTradeDateEpochUtc": 1616160600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f1aecc10-79bf-31c7-a21a-8af27158e95e", "messageBoardId": "finmb_706016439", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.39, "targetHighPrice": 7.99, "targetLowPrice": 6.0, "targetMeanPrice": 7.0, "targetMedianPrice": 7.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 2, "totalCash": 118704000, "totalCashPerShare": 2.154, "ebitda": -64233000, "totalDebt": 465000, "quickRatio": 4.892, "currentRatio": 4.986, "debtToEquity": 0.46, "returnOnAssets": -0.27071, "returnOnEquity": -0.46030998, "freeCashflow": -27069500, "operatingCashflow": -47930000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]